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e-mail address: val.white@vch.ca (V.A. White).Kaustubh Mulay, DNB a; Ekta Aggarwal, MS b; Valerie A. White, MD, MHSc, FRCPC c,⇑AbstractSebaceous gland carcinoma (SGC) is a rare tumour occurring at periocular and extra-ocular sites. SGC can be a challenging diag-
nosis for both clinicians and pathologists. High recurrence rates and a tendency for intra-epithelial spread, locoregional and distant
metastases make it important for SGC to be suspected and be included in the differential diagnosis of an eyelid lesion. Early diag-
nosis, that may sometimes need ancillary testing, and prompt management using a multimodal approach can help reduce mor-
bidity and mortality in patients with SGC.
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The sebaceous glands are microscopic glands in the skin
that secrete sebum. In humans, they are found abundantly
in the face and scalp although they are distributed through-
out all skin sites except palms and soles. Sebaceous glands
are associated with the hair follicle, arising at the junction
of the inferior portion of the follicle infundibulum and the
isthmus.1 Sebaceous gland proliferations include senile seba-
ceous gland hyperplasia, sebaceoma, sebaceous adenoma
and sebaceous gland carcinoma.2 First described by Allaire
in 1891, sebaceous gland carcinoma (SGC) accounts for less
than 1% of all cutaneous malignancies.3,4 SGC can masquer-
ade as other inflammatory lesions, and benign and malignant
tumours thus delaying diagnosis possibly leading to inappro-
priate management and an increase in morbidity and/or
mortality.
The purpose of this review is to summarize in a multifac-
eted manner the data available in the literature regardingthe epidemiology, aetiology, clinicopathological features,
molecular advancements, differential diagnosis, manage-
ment and prognosis of patients with periocular SGC.
Surgical anatomy
The eyelid can be divided into anterior and posterior
lamellae. The skin, orbicularis muscle, eyelashes, and their
follicles are present in the anterior lamella while the posterior
lamella contains the mucocutaneous junction, meibomian
gland orifices, and tarsal plate. Sebaceous glands are found
in the tarsal plate (upper and lower), caruncle and eye brow.
The glands of Zeis open into the hair follicles at the base of
eyelashes.
Epidemiology
SGC can occur in either the periocular location or at extra-
ocular sites with the periocular sites accounting for 75% of alle:
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glands, the glands of Zeis and the sebaceous glands of the
eyelid skin, with the former being most frequent. SGC arise
two to three times more frequently in the upper eyelid than
its lower counterpart due to the presence of more meibomi-
an glands in the upper eyelid compared to the lower eyelid.7
Other periocular sites include the eye-brow, caruncle, lacri-
mal gland and conjunctiva.6–10 The rate of SGC varies accord-
ing to the ethnicity of the population. In Caucasians, SGC are
rare accounting for less than 1–5.5% of eyelid malignan-
cies.11,12 On the contrary, in the Chinese and Japanese pop-
ulation, SGC is the second most common eyelid malignancy
with the highest reported rates being 39% and 37.5% respec-
tively.13,14 Similar studies in the Indian population and in Sin-
gapore report rates of 31.2% and 10.2% respectively.15,16
The reason for higher rates of SGC in the Asian population
could be genetic or racial in nature. Alternatively, the rates
of SGC could be higher due to the lower incidence of other
eyelid malignancies. The absolute incidence in non-Cauca-
sians is unknown. SGC is considered to be a tumour of the
older age group, mostly arising between the sixth and eighth
decades of life, although it can occur in younger age groups
as well.1,15 Some reports suggest a female preponderance
while others report no gender predilection.6,7,17,18
Aetiology
The aetiology of SGC is largely unknown. Several risk fac-
tors have been associated with this tumour. Asian race is re-
ported to be significantly associated with SGC.19–21 However,
recent reports suggest a contradictory observation of the tu-
mour being more common in whites thus suggesting the role
of sunlight exposure.17 Muir–Torre syndrome (MTS), a rare
genodermatologic disorder characterized by autosomal
dominant non-polyposis colorectal carcinoma, sebaceous
gland tumours and visceral malignancies is a risk factor for
SGC.22,23 Other reported associations include Rb and p53
mutations, HIV and HPV.24–27
Clinical features
The upper lid is more frequently involved by SGC than the
lower lid.7 It masquerades not only as various inflammatory
conditions such as blepharoconjunctivitis or chalazion but
also as premalignant lesions and other benign or malignant
tumours.28–31 The nodular form of SGC presents as a dis-
crete, hard, immobile nodule commonly located in the upper
tarsal plate having a yellowish appearance (Fig. 1A). The pag-
etoid variety of SGC occurs with intraepithelial infiltration of
the lid margin and/or conjunctiva causing diffuse thickening
and loss of eyelashes resembling chronic blepharoconjuncti-
vitis (Fig. 1B).32,33
Diagnosis, microscopy and immunostaining
It is important to include SGC in the differential diagnosis
of all eyelid lesions, particularly in populations with a higher
reported frequency. Microscopic examination is the gold
standard in diagnosis and confirmation of SGC. Most pa-
tients have a moderately differentiated tumour.34 The tumour
cells are arranged in the form of sheets or lobules, sometimes
with central comedo necrosis (Fig. 1C). Individual tumourcells have distinct cell membranes, clear to vacuolated cyto-
plasm and vesicular nuclei with prominent nucleoli, numerous
mitoses and apoptotic cells (Fig. 1D). The demonstration of
intracytoplasmic lipid vacuoles by Oil red O or Sudan IV
stains, performed on frozen sections of fresh or formalin-
fixed tissues is reported to aid in the diagnosis of SGC, but
is rarely necessary and has largely been superseded by
adipophilin (see below).6 Studies have reported a missed
diagnosis on light microscopy in 23–77% cases of poorly dif-
ferentiated SGC.35–37 Sometimes, the tissues are extremely
small or SGC may not be suspected before light microscopic
examination. In such situations, immunohistochemical stain-
ing helps in the diagnosis. A recent study reported that more
than 75% SGC stained positively for anti-CK5 and anti CK-15
and were negative with anti-CK1, CK10, CK15, CK17, CK18
and CK20 antibodies.38 Antibodies to phosphinothricin-N-
acetyl transferase (PAT) or perilipin family have been used
to demonstrate proteins associated with lipid droplets
(Fig. 1E).39 Adipophilin (ADP) had a lower specificity (77%)
but higher sensitivity (88.5%) as compared to perilipin (spec-
ificity 100%, sensitivity 45.5%) and tail-interacting protein of
47 kDa (TIP47, specificity 100%, sensitivity 8.3%).39 This study
also suggested that ADP was a more sensitive marker of lipid
droplets in SGC than Oil red O.39 However, a similar staining
pattern for ADP is also seen in xanthomatous lesions and
metastatic renal cell carcinoma.40 SGC are immunoreactive
for epithelial membrane antigen (EMA) with staining being
restricted to the centre of cell nests.34 BRST-1 antibody stains
most SGC, either focally or diffusely. It is negative in basal cell
carcinoma (BCC) but can be focally positive in squamous cell
carcinoma (SCC).34 Cam 5.2, an anti-low molecular weight
keratin antibody, is positive in most cases of SGC.34,41 It
can be positive in BCC but is negative in SCC.34 Immuno-
staining for androgen receptor (AR) in SGC has been exten-
sively described in the recent literature suggesting AR to
be a reliable marker of sebaceous differentiation
(Fig. 1F).42–46 A panel of antibodies comprising carcinoem-
bryonic antigen (CEA), EMA, AR, Ber-EP4, ADP, CA15-3
and CA19-9 has been suggested to differentiate SGC from
SCC and BCC (Table 1).39,40,43,46,47 Intra-epithelial spread, a
common cause of misdiagnosis, is a characteristic feature of
SGC seen in up to 39% patients.31 Intra-epithelial spread
can have a Bowenoid, pagetoid or mixed pattern. Reports
in the literature describe the Bowenoid and pagetoid pat-
terns in up to 35% and 47% of SGC respectively.36,48Molecular pathology
Muir-Torre syndrome and mismatch repair genes
Several studies have investigated the relationship be-
tween MTS and SGC.1,22,23,49 A subset of patients with clini-
cal or phenotypic MTS have a defect in the DNA mismatch
repair (MMR) genes and are at a risk for developing a future
malignancy.49 An MMR defect results in the accumulation of
replication errors or unstable microsatellite sequences.50 In
MTS, germline mutation in one of the MMR-genes is comple-
mented by a second somatic molecular alteration in a neo-
plasm. A sebaceous lesion is present either before or
concurrent with the first visceral malignancy in 63% patients
with MMR-deficient MTS.51 Diagnosis of SGC or a benign
sebaceous neoplasm should prompt the clinician to carry
Figure 1. Clinicopathological features of sebaceous gland carcinoma. Nodular form of sebaceous carcinoma involving both fornices (Fig. 1A) and
pagetoid variety presenting as diffuse thickening of the eyelid (Fig. 1B). Lobules of tumour cells with central comedo necrosis (Fig. 1C, haematoxylin and
eosin 40). Tumour cells with vacuolated cytoplasm and vesicular nuclei having prominent nucleoli (Fig. 1D, haematoxylin and eosin 400). Tumour cells
showing cytoplasmic staining for adipophilin (Fig. 1E, 400) and nuclear staining for androgen receptor (Fig. 1F, 400).
Table 1. Antibody panel that may be helpful in the differential diagnosis of sebaceous gland carcinoma, basal cell carcinoma and squamous cell carcinoma.
Antibody Sebaceous gland carcinoma Basal cell carcinoma Squamous cell carcinoma
CEA46 ±  
ADP39,40,43,46–48 +  
AR43,46 + ± 
EMA46,47 +  +
Ber-EP446  + 
CA19-946 ± ± 
CA15-346 +  ±
BRST134 + ± 
CAM5.234,47 +  ±
CEA, carcinoembryonic antigen; ADP, adipophilin; AR, androgen receptor; EMA, epithelial membrane antigen.
Periocular sebaceous carcinoma a review 161out a thorough history and physical examination to rule out a
visceral malignancy. It should also prompt the laboratory to
perform immunostaining for the commonly absent MMR pro-
teins (MSH2, MLH1, PMS1 and PMS2). One-third of patients
with clinical MTS demonstrate failure to express normal MMR
proteins.49 Mutations in MSH2 and MLH1 are more frequent
than those in MSH6, MSH3, MLH3, PMS2 and PMS1.1
Many cell signalling pathways have been shown to be dys-
regulated in SGC (Table 2 and Fig. 2).
Wnt/b-catenin pathway
The Wnt/b-Catenin pathway regulates stem cell pluripo-
tency and cell fate decisions during development. In the ab-sence of Wnt, glycogen synthase kinase 3 (GSK-3)
constitutively phosphorylates the b-catenin protein. Overex-
pression of b-catenin has been demonstrated in SGC thus
suggesting a possible dysregulation of the Wnt/b-catenin
pathway.52–54 Further, it was also shown that reduced mem-
branous expression of b-catenin correlated with invasion
and metastasis, especially at the site of invasion.54TP53
p53 Mutations in SGC, as demonstrated by overexpres-
sion, suggest a possible role of UV radiation and subsequent
signal alterations.25
Table 2. Signalling pathways and proteins involved in periocular sebaceous gland carcinoma.
Study group Protein
involved
Protein function Signal
pathway
Expression change Prognostic significance
Jayaraj et al.51 b-catenin Co-ordination of cell–cell adhesion
and gene transcription
Wnt/b-
catenin
Overexpression Correlated with tumour size >2 cm
Jayaraj et al.53 Reduced
membranous
expression
Invasion and metastasis
Shalin et al.25 p53 Apoptosis tumour suppressor
inhibits angiogenesis DNA repair
cell cycle arrest
p53 Overexpression Correlates with tumour type and
tumour location
McBride et al.54 p21WAF1 Cyclin-dependent kinase inhibitor. p53/p21
p53
independent
Loss of
compartmentalization
Preserved in benign and normal
sebaceous glands
Kiyosaki et al.55 Cell-cycle regulation Prevents cell
proliferation
Down regulation Lymph node metastasis
Kim et al.52 Shh
ABCG2
Maintenance of stem cells in adult
tissues
Sonic
hedgehog
Overexpression Metastatic disease Aggressiveness
Rokhlin et al.59,
Nantermet
et al.60
Androgen
receptor
Regulation of gene expression NA Increased activity Inhibits p53 expression and p53
activity.
Li et al.76 E-cadherin Suppressor of invasion and growth
of epithelial cancers. Cell–cell
adhesion
Wnt/ b-
catenin/TCF
Lower expression Poor tumour differentiation and high
proliferation rate
Jayaraj et al.53 Promoter methylation Reduced disease-free survival, size
>2 cm, lymphnode metastases, poor
differentiation
Figure 2. Sonic hedgehog and Wnt/b-catenin signalling pathways in sebaceous gland carcinoma.78.
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p21WAF1, a cyclin-dependent kinase inhibitor, regulates
G1-S transition and mediates G1 cell cycle arrest. It can be
transcriptionally upregulated by p53 but may be activated
independently. Compartmentalization of p21WAF1 in the dif-
ferentiated component of the gland, seen in normal seba-
ceous glands and benign sebaceous lesions, is lost in
SGC.55 A recent study associated downregulation of p21 with
lymph node metastasis in SGC.56Sonic hedgehog pathway
The sonic hedgehog (Shh) signalling pathway is also al-
tered in SGC with Shh and ABCG2 proteins being overex-
pressed in patients with a metastatic disease.53 This study
thus suggested that activation of Wnt and Shh signalling
pathways is associated with higher cumulative incidences of
lymph node and distant metastasis in SGC.53Androgen receptor
AR has been identified as a MYC target gene in mouse
epidermis.57 p53 can inhibit AR gene expression by direct
association with AR promoter58 and by inhibiting AR protein
activity.59 On the other hand, strong AR activity can inhibit
p53 expression60 and p53 activity.61 Thus, the expressions
of AR and p53 are inversely related to each other in SGC.62E-cadherin
E-cadherin promoter hypermethylation has been associ-
ated with poor clinical outcome.54,63Treatment
As discussed earlier, SGC may be a difficult clinical diag-
nosis to make due to its masquerading nature and thus,
might delay diagnosis and appropriate management. Local
Periocular sebaceous carcinoma a review 163excision, orbital exenteration, radiotherapy and chemother-
apy are various methods used to manage patients with
SGC based on tumour stage at presentation. Wide excision
with at least 4 mm margin and radical neck dissection is
necessary in patients with locoregional metastases.64 How-
ever, 32% cases recur even with a margin clearance of 5–
6 mm.65 Frozen section and Mohs’ micrographic surgery are
now used in specialized centres. Definitive margin excision
and minimal loss of surrounding normal tissue are advanta-
ges of Mohs’ surgery. A recent study suggested the use of
‘slow’’ Mohs’ surgery which uses paraffin embedded sections
to identify pagetoid spread that is otherwise difficult or
impossible to identify on frozen sections.66 A recurrence rate
of 11.1% has been reported after Mohs’ surgery.65 Exentera-
tion is the treatment of choice for patients with extensive or
multifocal tumour or extensive pagetoid spread.67 Radical
neck dissection is indicated in patients of SGC with regional
nodal metastases.7,64 The role of radiotherapy in SGC has
been extensively studied and found to have variable re-
sults.36,68–70 Radiation of 50–66.6 Gy administered with a
curative intent has been effective in achieving a prolonged
survival and good tumour control in addition to facilitating
functional and cosmetic preservation of the eyelid.68 Radio-
therapy given post-operatively following orbital exenteration
provides a better disease control as compared to treatment
by exenteration only.69 Radiation is best avoided due to the
various complications associated with it such as blepharocon-
junctivitis, lid atrophy, dry eye, ectropion, epiphora, cataract
and keratopathy.32 Cryotherapy may be used as a coadju-
vant.32 The role of Mitomycin C, a non-cell cycle specific alkyl-
ating agent, is controversial.71 It has been used in patients
with SGC and pagetoid spread to reduce the need for further
invasive management.72 More recently, neoadjuvant chemo-
therapy using carboplatin and 5-fluorouracil has been shown
to reduce morbidity in a patient with metastatic nodal dis-
ease.73 Recent studies on expression of oestrogen receptor
(ER), progesterone receptor (PR) and androgen receptor
(AR) suggest a potential role of hormonal therapy in patients
with SGC.42,43,74Prognosis
Various clinicopathological factors are reported to indi-
cate a poor prognosis in SGC and include lymphovascular
and orbital invasion, involvement of both upper and lower
eyelids, poor differentiation, multicentric origin, long dura-
tion of symptoms, large tumour size, an infiltrative pattern
and pagetoid invasion of epithelia of the skin or conjunctiva.7
The 7th edition of AJCC classification for eyelid tumours has
been shown to be prognostically useful in one study by Esma-
eli et al.75 and is in the process of being validated in a larger
cohort of patients. Tumours originating from the glands of
Zeis have a better prognosis.76 Also, origin from the upper
lids is associated with an adverse prognosis compared to ori-
gin from lower lids.76 Human telomerase RNA (hTR) has been
shown to be a marker of malignant degree in SGC.77 The
overall mortality rate in SGC is 5–10%.32 Locoregional metas-
tases and recurrence are seen in 6–29% cases.18,21,62,76 14–
25% patients develop metastases, either in the form of lym-
phatic spread to the lymph nodes and/or haematogenous
spread to the liver, lungs, brain, and bones.7,35,37,62,76Conclusion
Sebaceous gland carcinoma is a rare tumour of the eyelids
that can mimic many inflammatory and neoplastic lesions.
Accurate diagnosis by light microscopy and immunostaining
followed by appropriate management with a multimodal ap-
proach using surgical advances and adjuvant treatment pro-
vide good tumour control to reduce the morbidity and
mortality in these patients.Conflict of interest
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